{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T11:05:09Z","timestamp":1756811109741,"version":"3.40.3"},"reference-count":57,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anticancer Therapy"],"published-print":{"date-parts":[[2025,4,3]]},"DOI":"10.1080\/14737140.2025.2473645","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T03:05:03Z","timestamp":1740711903000},"page":"319-326","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["An evaluation of nivolumab plus gemcitabine and cisplatin in the treatment of advanced urothelial carcinoma"],"prefix":"10.1080","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9244-6672","authenticated-orcid":false,"given":"Eric J.","family":"Miller","sequence":"first","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai","place":["New York, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew D.","family":"Galsky","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai","place":["New York, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,3,4]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000000025"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2022.100661"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.12601"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21631"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)42494-3"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.7.1066"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.17.3068"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.8433"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.07.757"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00152-2"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30230-0"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01792"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2408154"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2158"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01003"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02568-1"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241249068"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312117"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309863"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.106"},{"key":"e_1_3_4_24_1","unstructured":"U.S. Food and Drug Administration. PADCEV\u00ae (enfortumab vedotin-ejfv) for injection for intravenous use [Internet]. 2023 [cited 2024 Jun 19]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761137s024s025lbl.pdf"},{"key":"e_1_3_4_25_1","unstructured":"Centers for Medicare & Medicaid Services. ASP pricing file [Internet]. 2024 Jul [cited 2024 Jun 21]. Available from: https:\/\/www.cms.gov\/files\/zip\/july-2024-asp-pricing-file.zip"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5057"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32542"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.3114"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS4618"},{"issue":"2","key":"e_1_3_4_30_1","first-page":"A693","article-title":"663\u2005Phase 2 multi-cohort clinical study evaluating disitamab vedotin alone and in combination with pembrolizumab in patients with HER2-expressing unresectable or metastatic urothelial carcinoma (RC48G001, trial in progress)","volume":"10","author":"Galsky M","year":"2022","unstructured":"Galsky M, O\u2019Donnell P, Burgess E, et al. 663\u2005Phase 2 multi-cohort clinical study evaluating disitamab vedotin alone and in combination with pembrolizumab in patients with HER2-expressing unresectable or metastatic urothelial carcinoma (RC48G001, trial in progress). J Immunother Cancer. 2022;10(Suppl 2):A693.","journal-title":"J Immunother Cancer"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.4565"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2019.102925"},{"key":"e_1_3_4_33_1","unstructured":"U.S. Food and Drug Administration. GEMZAR (gemcitabine) for injection for intravenous use [Internet]. 2019 [cited 2024 Jun 20]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/020509s082lbl.pdf"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-016-3003-0"},{"key":"e_1_3_4_35_1","unstructured":"U.S. Food and Drug Administration. OPDIVO (nivolumab) injection for intravenous use [Internet]. 2024 [cited 2024 Jun 21]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/125554s125lbl.pdf"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxm091"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-199512006-00006"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/0169-5002(95)00518-8"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008331111654"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.9.2876"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.9.1921"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.9861"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.6_suppl.439"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104059"},{"key":"e_1_3_4_45_1","unstructured":"Bristol Myers Squibb. Bristol Myers Squibb receives European commission approval for Opdivo\u00ae (nivolumab) in combination with Cisplatin and gemcitabine for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma [Internet]. 2024 [cited 2024 Jun 21]. Available from: https:\/\/news.bms.com\/news\/corporate-financial\/2024\/Bristol-Myers-Squibb-Receives-European-Commission-Approval-for-Opdivo-nivolumab-in-Combination-with-Cisplatin-and-Gemcitabine-for-the-First-Line-Treatment-of-Adult-Patients-with-Unresectable-or-Metastatic-Urothelial-Carcinoma\/default.aspx#:~:text=Metastatic%20Urothelial%20Carcinoma- Bristol%20Myers%20Squibb%20Receives%20European%20Commission%20Approval%20for%20Opdivo\u00ae Unresectable%20or%20Metastatic%20Urothelial%20Carcinoma"},{"key":"e_1_3_4_46_1","unstructured":"United Kingdom medicines and healthcare products regulatory agency. OPDIVO 10 mg\/mL concentrate for solution for infusion [Internet]. 2024 [cited 2024 Oct 29]. Available from: https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/c90345967304b0cb3f2128e8237613ad9ef02206"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr156"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007613"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1298"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-3141"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-0724"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101393"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.03.003"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00667-z"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-2275"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.4509"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.16319"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI43656"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI40269"}],"container-title":["Expert Review of Anticancer Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737140.2025.2473645","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T09:48:24Z","timestamp":1743500904000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737140.2025.2473645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,4]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,3]]}},"alternative-id":["10.1080\/14737140.2025.2473645"],"URL":"https:\/\/doi.org\/10.1080\/14737140.2025.2473645","relation":{},"ISSN":["1473-7140","1744-8328"],"issn-type":[{"type":"print","value":"1473-7140"},{"type":"electronic","value":"1744-8328"}],"subject":[],"published":{"date-parts":[[2025,3,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-11-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}